fuzzyjr...Thanks.

I was going to go back through the history and details and sum them up but you have captured it for me.

Here we have a situation of incredible scientific progress. Resverlogix is leading edge in BET inhibition for CVD and in phase 3 BETonMACE and yet the stock languishes.

When I think about rvx-208 and it's cascading epigenetic effects this must be very difficult for scientists and investors to absorb. What I am trying to express by this is that rvx-208 as released on Nov 30th, 2015 is that "rvx-208 lowers MACE in CVD patients and especially in ones with DM. rvx-208 inhibits BET proteins to affect many biological processes underlying CVD such as; reverse cholesterol transport, vascular inflammation, innate immunity, atherosclerosis and thrombosis in lowering MACE".

We all know the stock is undervalued significantly for a phase lll trial drug.

There are a number of factors which could impact the stock price in the future in between the BETonMACE results in 2019 and they include;

1. The orphan trial on PNH - Paroxysmal Nocturnal Hemoglobinuria.
2. The fact that AZ may finally understand the RVX patents with rvx-208 and Crestor.
3. The fact that this year the deal with Hepalink creates a new strategy for transforming RVX into a downstream marketing company.
4. The next regional deal.
5. The multiple applications of the drug.
6. Improved analyst coverage.
7. NASDAQ listing.
8. BETonMACE is well financed.
9. The clinical team id full of top scientists.
10. BETonMACE dosing has started in November of 2015.
11. Business development partnerships are in progress.

So I was going to try to summarize all of the achievements but I think you have captured them.

I don't know if there is going to be any money made on this stock until 2019, or so, but some factors could push the value.

So GLTA in 2016.

Cheers

Toinv